Clinical trials: Plasma Cell Myeloma, open to volunteers
Blood Cancer, Lymphoma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function.
- Conditions
- Blood Cancer, Lymphoma, Leukemia, Myeloma
- Trial name
- NCT07052916
- Testing
- Music Therapy/MT, Therapist-Attention Music Education/TAME Control
- Where
- 7 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Plasma Cell Leukemia
Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
Single-Arm phase 2 trial evaluating efficacy of incorporating Daratumumab to treatment of newly diagnosed primary plasma cell leukemia.
- Trial name
- PCL-2 (NCT05054478)
- Testing
- Daratumumab
- Volunteers
- 29 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
AL Amyloidosis, Smoldering Multiple Myeloma
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1.
- Conditions
- AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ProDigALIty (NCT06383143)
- Testing
- no intervention
- Where
- 4 sites in Italy
- Volunteers
- 760 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Plasma Cell Myeloma Refractory
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the…
- Trial name
- NCT06630806
- Testing
- SAR446523
- Where
- 19 sites in United States, Australia and 5 more
- Volunteers
- 87 people
- Sponsor
- Sanofi
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
This phase II trial tests alternate doses and dosing schedules of belantamab mafodotin in treating patients with triple-class multiple myeloma that has come back (after a period of improvement) (recurrent) and/or does not respond…
- Trial name
- NCT05847569
- Testing
- Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Mayo Clinic
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Bergamo Lymphoid Cancer Registry
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
- Conditions
- Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma
- Trial name
- NCT03131531
- Testing
- Patient registry
- Where
- Italy
- Volunteers
- 6,000 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis…
- Trial name
- ROTATE (NCT06993675)
- Testing
- Talquetamab, Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Noffar Bar
Multiple Myeloma, Cancer
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM).
- Trial name
- NCT05145400
- Testing
- Isatuximab, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Relapsed or Refractory Multiple Myeloma
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the…
- Trial name
- NCT07681596
- Testing
- AZD4045, Daratumumab, Aldesleukin
- Where
- 12 sites in United States, Australia
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Multiple Myeloma
Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection
This is an open-label, multicenter, observational study (non-interventional study) to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F Injection
- Trial name
- NCT07833046
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Multiple Myeloma
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase…
- Trial name
- IMMUNOPLANT (NCT06376526)
- Testing
- Linvoseltamab
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dickran Kazandjian, MD
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received…
- Trial name
- CEVOLUTION (NCT07555938)
- Testing
- Cevostamab, Pomalidomide, Dexamethasone
- Where
- 93 sites in United States, Australia and 16 more
- Volunteers
- 380 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with…
- Trial name
- LINKER-MM4 (NCT05828511)
- Testing
- Linvoseltamab
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 149 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
The Ambient Light Multiple Myeloma Study
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients…
- Trial name
- NCT05737732
- Testing
- Circadian Effective Lighting, Circadian Ineffective Lightning (CIL)
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Multiple Myeloma, DRD
A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients
The goal of this study is to observe and evaluate the incidence of infection in newly diagnosed, non-transplanted multiple myeloma patients receiving prophylactic treatment with sulpegfilgrastim (a pegylated recombinant human…
- Conditions
- Multiple Myeloma, DRD, Sulpegfilgrastim, Neutropenia
- Trial name
- NCT07018271
- Testing
- sulpegfilgrastim
- Volunteers
- 24 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture.
- Trial name
- NCT06196255
- Testing
- anti-FcRL5 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuzhou Medical University
Multiple Myeloma
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future.
- Trial name
- NCT00898235
- Testing
- clonality analysis, polymerase chain reaction, protein analysis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Boston Medical Center
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
This study aims to study the efficacy and safety of oral cyclophosphamide in addition to carfilzomib and dexamethadone for RRMM patients who have been previously exposed to lenalidomide combination therapies.
- Trial name
- KMM-KCd (NCT05909826)
- Testing
- Carfilzomib, Cyclophosphamide, Dexamethasone
- Volunteers
- 49 people
- Sponsor
- Dong-A University Hospital
Leukemia, Lymphoma
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS)
- Trial name
- PROACTIVE (NCT04898790)
- Testing
- CHAMPS-II adapted to adults 60+ years in HCT setting
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- University of Nebraska